Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health develops, manufactures and markets animal health products for farm animals and pets. News about ELAN commonly covers operating and financial results, product launches in pet health and livestock health, and regulatory actions involving animal medicines and parasite-control products.
Company updates also include capital-structure disclosures, investor conference presentations, and governance changes tied to Elanco's board and public-company operations. Product-specific developments have included the Advantage brand for dogs and emergency-authorized livestock treatments such as Negasunt Powder and Tanidil.
Elanco (ELAN) reports that innovation in parasiticide and dermatology products is driving stronger base business, price acceleration and market share gains in 2026, with U.S. Pet Health on track for previously communicated high-single digit to low double-digit revenue growth in the second half of the year.
In the first half of 2026, U.S. and International Pet Health each delivered 9% organic constant currency revenue growth year over year, with reported growth of 9% and 15%, respectively. Elanco cites share gains across all four major U.S. categories—dermatology, parasiticides, osteoarthritis pain and vaccines—and roughly 1,100 additional Credelio Quattro clinics quarter-to-date (July–August). Internationally, dermatology revenue grew 9% in the first half of 2026 and Zenrelia gained 10 share points in Europe. The legacy base portfolio has improved from mid- to high-single digit declines in 2023–2024 to around plus or minus low-single digit levels currently and expected forward.
Elanco Animal Health (ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026. On the same day, the company will host a conference call for investors, media, and the public, starting at 8:00 a.m. Eastern time, with a live webcast and replay available via its investor relations website.
Elanco (ELAN) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.
President and CEO Jeff Simmons, executive vice president and CFO Bob VanHimbergen, and executive vice president U.S. Pet Health and Global Digital Transformation Bobby Modi will join a fireside chat at 2:35 p.m. ET that day. A live audio webcast will be accessible through the “Events and Presentations” section of Elanco’s investor website, with a replay available for a limited time after the event.
Elanco (NYSE: ELAN) announced the on-time completion of a 25,000-square-foot expansion at its Elwood, Kansas manufacturing site, focused on monoclonal antibody (mAb) production. The project represents a $120 million investment and increases production capacity by more than four times.
The facility manufactures Befrena, an anti-IL-31 mAb for canine allergic and atopic dermatitis, and Trutect, a therapeutic for canine parvovirus. Elanco reported Befrena demand at twice expectations and expects unconstrained supply in early 2027. The expansion adds a pilot plant, quality control lab and support spaces, with an additional $30 million investment planned through 2028, including new warehousing.
Elanco (NYSE: ELAN) announced that the U.S. FDA has granted an Emergency Use Authorization (EUA) for CLiK Extra (dicyclanil topical suspension) wound spray to prevent New World screwworm larvae infestations on or around wounds in sheep, cattle, goats, swine, camelids, and specified captive and captured wildlife, including cervids, American bison, bighorn sheep and Sonoran pronghorn.
According to Elanco, CLiK Extra is for prevention only and does not treat active infestations, has an 86‑day slaughter/harvest restriction for several species, and cannot be used in animals producing milk for human consumption. Elanco also highlights separate emergency authorizations and safety restrictions for Negasunt Powder and Tanidil, plus availability of EPA‑registered Catron IV.
Elanco Animal Health (NYSE: ELAN) reported second quarter 2026 revenue of $1.368 billion, up 10% year-over-year, or 8% on an organic constant currency basis. Pet Health rose 12% to $718 million and Farm Animal 9% to $633 million, with global ruminants the fastest-growing species.
Reported net income was $54 million (EPS $0.11) versus $11 million (EPS $0.02) a year ago. Adjusted net income reached $174 million (EPS $0.34), up 31%, and adjusted EBITDA was $288 million, up 21%, lifting adjusted EBITDA margin to 21.2%. Gross margin expanded about 80 basis points, supported by U.S. Pet Health and pricing.
Cash from operations increased to $277 million, and net leverage improved to 3.1x adjusted EBITDA, 0.5x lower than year-end 2025. Elanco raised its 2026 guidance, now expecting revenue of $5.09–$5.14 billion, adjusted EBITDA of $1.01–$1.035 billion, and adjusted EPS of $1.10–$1.16, alongside an improved year-end net leverage target of roughly 3.0x.
Elanco (NYSE: ELAN) released its 2025 Impact Report, “Leading with Purpose,” detailing progress across four areas: animals, customers, society and its people. The company generated $892 million in 2025 revenue from new innovation, led by Credelio Quattro, Zenrelia, Experior and AdTab, and reports 5–6 blockbuster‑potential approvals targeted by 2031 with unprobabilized potential peak sales above $2 billion.
Elanco highlights Credelio Quattro as its fastest pet health blockbuster, treatment of over 2 million itchy dogs with Zenrelia, and emergency and conditional authorizations against New World screwworm. The company helped feedyards quantify carbon-reduction interventions for 1.4 million cattle, achieving more than 200,000 metric tons of CO₂e reductions, and advanced Salmonella control in 23 countries. Additional data include recovery of more than 160,000 counterfeit products worth over $13 million, a 73% employee engagement score, over 28,000 volunteer hours and support for 938 nonprofits.
Elanco (NYSE: ELAN) reported new peer-reviewed data showing that Credelio Quattro (lotilaner, moxidectin, praziquantel, pyrantel) achieves significantly faster tick kill than Simparica Trio and NexGard Plus. Against black-legged ticks, Credelio Quattro was the only product to reach significant reduction within 8 hours, maintaining this speed through Day 28 of the monthly dosing period.
Lotilaner also provided the fastest initial kill of lone star ticks in 12 hours versus sarolaner and afoxolaner and sustained superiority throughout the interval. Credelio Quattro carries an FDA-approved claim for prevention of Lyme disease in dogs via killing black-legged ticks and is indicated for multiple internal and external parasites, with detailed safety warnings for neurologic and gastrointestinal adverse events.
Elanco (NYSE: ELAN) will release its second quarter 2026 financial results on Wednesday, August 5, 2026. A conference call for investors, media, and the public will be held the same day at 8:00 a.m. Eastern Time, with live webcast and replay available on Elanco's investor website.
Elanco (NYSE: ELAN) plans to launch Elanco Ventures, a corporate venture capital platform backed by a $25 million multi-year commitment to invest in animal health innovation. Initial focus areas include therapeutic advancements, supportive technologies and selected One Health opportunities, targeting early-stage startups from Pre-Seed through Series A.
Launching in late 2026, Elanco Ventures will be led by Eric Steager and will leverage collaboration within Indianapolis’ One Health Innovation District, anchored by Elanco and Purdue University, to connect life sciences, researchers and entrepreneurs and help accelerate new solutions in animal health.